Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dirk Huebner, Abraham Fong, Anas Younes

Blood (2016) 128 (12): 1562–1566.

https://doi.org/10.1182/blood-2016-02-699850

Published: 2016

Includes: Supplemental data

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, Stephen Ansell, MD PhD, Joseph D. Rosenblatt, Kerry J. Savage, MDMSc, Joseph M. Connors, MD, Andreas Engert, Emily K Larsen, Dirk Huebner, Abraham Fong, Anas Younes, MD

Blood (2015) 126 (23): 2736.

https://doi.org/10.1182/blood.V126.23.2736.2736

Published: 2015

Journal Articles

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Ajay K. Gopal, Robert Chen, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Xuedong Chi, Eric L. Sievers, Anas Younes

Blood (2015) 125 (8): 1236–1243.

https://doi.org/10.1182/blood-2014-08-595801

Published: 2015

Includes: Supplemental data

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Ajay K. Gopal, MD, Robert Chen, MD, Scott E. Smith, MD, PhD, Stephen M Ansell, M.D.Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dirk Huebner, MD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2013) 122 (21): 4382.

https://doi.org/10.1182/blood.V122.21.4382.4382

Published: 2013

Journal Articles

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, Stephen M. Ansell, M.D., Ph.D., Joseph D. Rosenblatt, MD, Kerry J. Savage, MD MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Eric L. Sievers, MD, Anas Younes, MD

Blood (2012) 120 (21): 3689.

https://doi.org/10.1182/blood.V120.21.3689.3689

Published: 2012

Journal Articles

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, MD, PhD, FACP, Stephen M. Ansell, MD, PhD, Joseph D. Rosenblatt, MD, Richard Klasa, MD, CM, FRCP(C), Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dana A. Kennedy, PharmD, Eric L. Sievers, MD, Anas Younes, MD

Blood (2010) 116 (21): 283.

https://doi.org/10.1182/blood.V116.21.283.283

Published: 2010

NARROW

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only